Open in app

First indigenously created vaccine for cervical cancer in India is approved by a government panel.

Total Views:
Total Likes:
Published By:
Peeyush Ghalot
Published On:
(Image Courtesy: - Deccan Herald)

The quadrivalent human papillomavirus (qHPV) vaccine produced locally by Serum Institute is advised for cervical cancer patients between the ages of 9 and 26 by the DCGI's Subject Expert Committee on Wednesday. After completing the phase 2/3 clinical trial with assistance from the Department of Biotechnology, Prakash Kumar Singh, director (government and regulatory affairs) at SII, applied to the Drugs Controller General of India (DCGI) on June 8 for market authorisation of qHPV in order to ensure its quick availability in the nation. The CDSCO's Subject Expert Committee (SEC) on COVID-19, which met to discuss the application, recommended that Serum Institute be given market authorization to produce qHPV to prevent cervical cancer. According to information obtained from Singh's submission to the DCGI, the qHPV vaccine CERVAVAC has shown a strong antibody response that is more than 1,000 times greater than the baseline against all targeted HPV types, in all doses, and across all age groups. It's also been reported that the Serum Institute spoke before the HPV working group, which the NTAGI independently formed to study the evidence and assess the efficacy of this vaccination.

Reference: -